anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic cough is a common symptom in patients post the coronavirus disease 2019 (COVID-19). In this study, we aimed to investigate the efficacy of inhaled corticosteroids (ICS) and the clinical characteristics of patients with post-COVID-19 chronic cough during the Omicron era.
METHODS: An ambispective, longitudinal cohort study was conducted that included patients with post-COVID-19 who attended the respiratory clinic at our hospital between January 1, 2023, and March 31, 2023 with a complaint of persistent cough lasting more than 8 weeks. At 30 and 60 days after the first clinic visit for post-COVID-19 chronic cough, enrolled patients were prospectively followed up. We compared the changes in symptoms and pulmonary function between patients receiving ICS treatment (ICS group) and those not receiving ICS treatment (NICS group) at the two visits.
RESULTS: A total of 104 patients with post-COVID-19 chronic cough were enrolled in this study (ICS group, n = 51; NICS group, n = 53). The most common symptoms accompanying post-COVID-19 chronic cough were sputum (58.7%, 61/104) and dyspnea (48.1%, 50/104). Seventy-one (82.6%, 71/86) patients had airway hyperresponsiveness, and 49 patients (47.1%, 49/104) were newly diagnosed with asthma. Most patients (95.2%, 99/104) exhibited improvement at 60 days after the first visit. The pulmonary function parameters of the patients in the ICS group were significantly improved compared to the baseline values (P < 0.05), and the improvement in the FEV1/FVC was significantly greater than that in the NICS group (P = 0.003) after 60 days.
CONCLUSIONS: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may contribute to the pathogenesis of asthma, which could be the underlying cause of persistent cough post-COVID-19 infection. Post-COVID-19 chronic cough during the Omicron era was often accompanied by sputum, dyspnea, and airway hyperresponsiveness. ICS treatment did not have a significant impact on symptom management of post-COVID-19 chronic cough; however, it can improve impaired lung function in in these individuals.
The invention relates to a novel CTHRC1 nucleic acid and protein encoded thereby. Expression of CTHRC1 is induced by injury in, among others, arteries and skin, and CTHRC1 is expressed in bone, cartilage, kidney, lung and brain. CTHRC1 expression is associated with collagen matrix production, arterial remodeling, arterial restenosis, constrictive remodeling, vessel injury, ectopic ossification, fibrosis, and the like. CTHRC1 also plays a role in cell-cell and cell-matrix adhesion, cell-migration, and bone, cartilage, skin and brain development. CTHRC1 also regulates the level of BMPs, including BMP1 and BMP4, and the invention encompasses methods relating to affecting the level of BMPs by affecting the level of CTHRC1. In addition, the invention relates to modulation of the level of CTHRC1 to affect processes associated with fibrosis mediated by formation of collagen matrix. The invention further relates to methods of treating, preventing, and/or detecting these diseases, disorders or conditions, where the methods comprise modulating or detecting CTHRC1 expression and/or production of CTHRC1 polypeptide. The invention also relates to affecting CTHRC1 expression using cytokines.
The purpose was to investigate how well age-adjusted modified quick Sequential Organ Failure Assessment (qSOFA) scores paired with blood glucose and lactate levels predict the outcomes of septicemic children in the pediatric intensive care unit (PICU). One hundred children who were diagnosed with sepsis and septic shock in the PICU of Henan Children's Hospital were eligible, and other 20 patients in the same hospital at different times were selected as a validation set. Respiratory rate (RR), heart rate (HR), capillary refill time (CRT), and Alert, Voice, Pain, Unresponsive (AVPU) scale were included in the age-adjusted modified qSOFA scoring criteria for scoring. The primary outcome was 28-day all-cause mortality. The predictive values were evaluated by the ROC curve. In the sepsis group, 50 patients were male, and 50 patients were female. The 28-day all-cause mortality rate was 52%. Fifty-one patients with age-adjusted modified qSOFA scores >1. The serum lactate level was 2.4 mmol/L, and the blood glucose level was 9.3 mmol/L. The AUCs for the age-adjusted modified qSOFA score, serum lactate and blood glucose levels for the prediction of 28-day all-cause mortality in children with sepsis were 0.719, 0.719 and 0.737, respectively. The cut-off values were one point, 3.8 mmol/L and 10 mmol/L, respectively. The AUC of the age-adjusted modified qSOFA score for the validation set of was 0.925. When the three indices were combined, the AUC was 0.817, the Hosmer-Lemeshow goodness-of-fit test showed χ2 = 2.428 and p = .965. When children with sepsis are admitted to the ICU, we recommend performing rapid scoring and rapid bedside lactate and glucose testing to determine the early prognosis.
Metamemory, or the ability to understand the capacities of one's own memory, is important for learning. To investigate questions surrounding metamemory, researchers commonly have participants make judgments of learning (JOLs) at encoding, in which participants rate their likelihood of recalling the target in a cue-target word pair when shown only the cue at test. However, the associative direction of cue-target pairs can affect the calibration of JOLs. Unlike forward associates (e.g., credit-card), in which JOLs often accurately predict recall, an illusion of competence has been reported for backward associates (e.g., card-credit), symmetrical associates (e.g., salt-pepper), and unrelated cue-target pairs (e.g., artery-bronze) such that JOLs overestimate later recall. The present study evaluates whether the illusion of competence can be reduced when participants apply deep item-specific or relational encoding tasks relative to silent reading. Across two experiments, we show that both item-specific and relational encoding strategies reduce the illusion of competence for backward associates and unrelated pairs while improving the calibration between JOLs and recall. Our findings suggest that these encoding strategies are effective at reducing the illusion of competence, with increased calibration primarily reflecting improved recall. Thus, item-specific and relational encoding strategies primarily affect retrieval processes rather than metacognitive processes that participants engage in at encoding.
Features are disclosed for training a machine learning model to identify objects in histological images. A system may obtain an image and determine a number of objects in the image. For example, the system may determine a percentage of objects in the image with a particular object type. Further, the system may determine a weight. The weight may specify a percentage of the image occupied by objects with the particular object type. The system can generate training set data that includes the image, data identifying the number of objects in the image, and the weight. The system can use the training set data to train a machine learning model to predict a number of objects in a different image and a weight. The system can implement the machine learning model based on training the machine learning model.
PURPOSE:To obtain a low-cost cell immunity stimulant capable of enhancing the cell immunological function, especially the migration and the phagocytosis of phagocytes by oral administration to an animal and excellent in safety. CONSTITUTION:This cell immunity stimulant for mammals and poultries contains a soap bark extract as the active component. As the soap bark extract, an extract solution obtained by grinding the bark of Quilla ja Saponaria Mol. and extracting the ground material with water or an organic solvent such as ethanol, methanol or hexane and a powdery extract of soap bark obtained by condensing and drying the extract solution are exemplified. The migration function and the phagocytosis of phagocytes can be remarkably activated by adding this cell immunity stimulant to a feed or a food and orally administrating it to a mammal or a poultry. Accordingly, the host defense mechanism of the mammal or the poultry is improved and a preventive effect on infectious diseases can be expected.
Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
Peptide-antibody complexes, including fusions and conjugates, that target or accumulate in target cells, such as tumors and diseased cells, or enhance the immune system are disclosed. In some embodiments, such complexes function as platforms for attaching and targeting one or more therapeutic agents or detectable agents, including radioisotopes, detectable labels, and/or cytotoxic agents, to target cells in the central nervous system or across the blood brain barrier, cancerous cells, or target cells recognized by the antibody in such complexes. In some complexes, the peptide serves as the targeting mechanism, while other embodiments contemplate the antibody as the targeting mechanism. Peptides and/or antibodies can be engineered to deliver various effector functions in various embodiments. Peptide-antibody complexes that function as immunotherapies and enhance a body's immune system in detecting and/or destroying diseased cells or pathogens are also disclosed. Pharmaceutical compositions and uses of peptide-antibody complexes are further disclosed.
TRIUMEQ and TRIUMEQ PD are not recommended for patients with creatinine clearance <30 mL/min and pediatric patients with a similar degree of renal impairment based on age-appropriate assessment of renal function because TRIUMEQ and TRIUMEQ PD are fixed-dose combinations, and the dosage of the individual components cannot be adjusted. If a dose reduction of lamivudine, a component of TRIUMEQ and TRIUMEQ PD, is required for patients with creatinine clearance <30 mL/min and in pediatric patients with a similar degree of renal impairment based on age-appropriate assessment of renal function, then the individual components should be used [see Clinical Pharmacology (12.3)].

Patients with a creatinine clearance between 30 and 49 mL/min receiving TRIUMEQ may experience a 1.6- to 3.3-fold higher lamivudine exposure (AUC) than patients with a creatinine clearance ≥50 mL/min. There are no safety data from randomized, controlled trials comparing TRIUMEQ to the individual components in patients with a creatinine clearance between 30 and 49 mL/min who received dose-adjusted lamivudine. Additionally, there are no data available on the use of lamivudine in pediatric patients with renal impairment. In the original lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were associated with higher rates of hematologic toxicities (neutropenia and anemia), although discontinuations due to neutropenia or anemia each occurred in <1% of subjects.

Patients with a sustained creatinine clearance between 30 and 49 mL/min or pediatric patients with a similar degree of renal impairment based on an age-appropriate assessment of renal function who receive TRIUMEQ or TRIUMEQ PD should be monitored for hematologic toxicities. If new or worsening neutropenia or anemia develop, dose adjustment of lamivudine, per lamivudine prescribing information, is recommended. If lamivudine dose adjustment is indicated, TRIUMEQ or TRIUMEQ PD should be discontinued, and the individual components should be used to construct the treatment regimen.
Participants identified from the Dane County Juvenile Court Program will be asked to experience up to 6 VR-B sessions. Participants will wear a lightweight, ultra-high-resolution, wireless, head-mounted display (Oculus Quest 2 Enterprise VR Headset). Each session will proceed through a series of four stages. First, participants will begin with a 5 minute acclimation period inside a demo VR environment. Second, baseline levels of physiological arousal will be captured over a 5 minute resting period where participants will be asked to sit quietly in a serene virtual environment. Third, participants will progress through the DEEP VR experience for 15 minutes. Finally, participants will complete a short series of online questionnaires.
Primary interest for combining SU011248 w irinotecan in malignant glioma pts derives from dramatic anti-tumor activity recently demonstrated among RMG pts treated w humanized anti-VEGF monoclonal antibody, bevacizumab, when combined w irinotecan. 63 percent radiographic response rate was observed following treatment w regimen every other wk, \& median progression-free survival was 23wks. Similar enhancement of chemo activity by VEGF-directed therapy w bev has been previously demonstrated for colorectal \& lung cancer pts. SU011248 is being evaluated in current regimen because it may exert more potent anti-angiogenic effect than bev among MG pts due to its ability to inhibit PDGFR-mediated pericyte stabilization in tumor neovasculature.

Current proposed ph I study is designed to determine MTD \& DLT of SU011248 when combo w irinotecan for pts w RMG. Both SU01148 \& irinotecan are known to be metabolized by CYP3A4 cytochrome system. Current study will limit enrollment to pts who are not on CYP3A4-enzyme inducing anti-epileptic drugs.
The invention provides a manufacturing method of a cucumber-egg whitening mask. The cucumber-egg whitening mask is prepared from cucumber, honey, egg white and essential balm. Cucumber has effects of cleaning and protecting skin and smoothing and unfolding wrinkles. Honey has effects of maintaining beauty and moistening skin. Egg has effects of whitening skin. The cucumber-egg whitening mask has a low cost, can be prepared by simple and convenient processes and has substantial use effects. The manufacturing method comprises cleaning cucumber, carrying out peeling, cutting the cucumber to obtain small blocks, putting the cucumber blocks, honey and essential balm into a food processer, carrying out crushing to obtain cucumber paste, adding egg white into the cucumber paste so that the cucumber paste is thick, and carrying out stirring to obtain a uniform mixture. After face washing, the face is coated with a thin makeup cotton layer, the prepared mask is pasted to the makeup cotton, the user lies down and takes a rest for 15-20min, the makeup cotton and the mask are removed and the face is cleaned by clear water.
Patients with end-stage kidney disease (ESKD) have a high symptom-burden and high rates of morbidity and mortality. Despite this, evidence has shown that this patient group does not have timely discussions to plan for deterioration and death, and at the end of life there are unmet palliative care needs. Advance care planning is a process that can help patients share their personal values and preferences for their future care and prepare for declining health. Earlier, more integrated and holistic advance care planning has the potential to improve access to care services, communication, and preparedness for future decision-making and changing circumstances. However, there are many barriers to successful implementation of advance care planning in this population. In this narrative review we discuss the current evidence for advance care planning in patients on dialysis, the data around the barriers to advance care planning implementation, and interventions that have been trialled. The review explores whether the concepts and approaches to advance care planning in this population need to be updated to encompass current and future care. It suggests that a shift from a problem-orientated approach to a goal-orientated approach may lead to better engagement, with more patient-centred and satisfying outcomes.
Adults

The recommended dose of INVEGA (paliperidone) Extended-Release Tablets for the treatment of schizophrenia in adults is 6 mg administered once daily. Initial dose titration is not required. Although it has not been systematically established that doses above 6 mg have additional benefit, there was a general trend for greater effects with higher doses. This must be weighed against the dose-related increase in adverse reactions. Thus, some patients may benefit from higher doses, up to 12 mg/day, and for some patients, a lower dose of 3 mg/day may be sufficient. Dose increases above 6 mg/day should be made only after clinical reassessment and generally should occur at intervals of more than 5 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day. ®

In a longer-term study, INVEGA has been shown to be effective in delaying time to relapse in patients with schizophrenia who were stabilized on INVEGA for 6 weeks . INVEGA should be prescribed at the lowest effective dose for maintaining clinical stability and the physician should periodically reevaluate the long-term usefulness of the drug in individual patients. ®®[see ] Clinical Studies (14)®

Adolescents (12–17 years of age)

The recommended starting dose of INVEGA (paliperidone) Extended-Release Tablets for the treatment of schizophrenia in adolescents 12–17 years of age is 3 mg administered once daily. Initial dose titration is not required. Dose increases, if considered necessary, should be made only after clinical reassessment and should occur at increments of 3 mg/day at intervals of more than 5 days. Prescribers should be mindful that, in the adolescent schizophrenia study, there was no clear enhancement to efficacy at the higher doses, i.e., 6 mg for subjects weighing less than 51 kg and 12 mg for subjects weighing 51 kg or greater, while adverse events were dose-related. ®
BACKGROUND: Gestational trophoblastic disease (GTD) is an uncommon but highly treatable condition. There is limited local evidence to guide therapy.
AIMS: To report the experience of a statewide registry in the treatment of low-risk gestational trophoblastic neoplasia (GTN) over a 20-year period.
MATERIALS AND METHODS: A retrospective review of the prospectively maintained GTD registry database was conducted. There were 144 patients identified with low-risk GTN, of which 115 were analysed. Patient demographics, treatment details and outcomes, including development of resistance, toxicity or relapse were reviewed.
RESULTS: The incidence of GTD was 2.6/1000 live births. There was 100% survival. The mean time from diagnosis to commencing treatment was 1.9 days (range 0-29 days). Seventy-seven percent of patients treated with methotrexate achieved complete response. Thirteen patients (11.3%) required multi-agent chemotherapy, for the treatment of resistant or relapsed disease. There was a higher rate of treatment resistance in those with World Health Organization (WHO) risk scores 5-6 (odds ratio (OR) 6.56, 95% CI 1.73-24.27, P = 0.005) and those with pre-treatment human chorionic gonadotropin >10 000 (OR 4.00 95% CI 1.73-24.27 P = 0.007). Four patients (3.5%) were diagnosed with choriocarcinoma after commencing treatment. Nine patients (7.8%) had successful surgical treatment for GTN, both alone and in combination with chemotherapy. The relapse rate was 4.3%; all were treated successfully with a combination of chemotherapy and surgery, and 93.9% of patients completed follow up through the registry.
CONCLUSIONS: Methotrexate is a highly effective treatment for low-risk GTN, especially with WHO risk score ≤4. The optimal treatment for those with risk scores of 5-6 requires further investigation.
Storage Conditions   
Rocuronium Bromide Injection should be stored in a refrigerator, 2° to 8°C (36° to 46°F). Do not freeze. Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use rocuronium bromide within 60 days. Use opened vials of rocuronium bromide within 30 days.

Safety and Handling  
There is no specific work exposure limit for Rocuronium Bromide Injection. In case of eye contact, flush with water for at least 10 minutes.
PURPOSE:To obtain an inexpensive and safe carcinostatic-containing fatty emulsion having high local action of carcinostatic and high medicinal effect, by making a fat-soluble carcinostatic and an oily component with an emulsifying agent selected from phospholipid, lecithin, lysolecithin, etc. into an emulsion having specific average particle diameter. CONSTITUTION:A fat-soluble carcinostatic agent (e.g., hexamethylemelamine, daunorubicin, palmitic acid complex, etc.) and an oily component (e.g., soybean oil, corn oil, etc.) are blended with an emulsifying agent, to give the titled emulsion having 0.05-0.4mu. The meulsifying agent is selected from phospholipid, hydrogenated phospholipid, lecithin, hydrogenated lecithin, lysolecithin, and an nonionic high polymer surface active agent having 800-2,000mol.wt. 6-30C fatty acid, its salt, or monoglyceride is used as an emulsifying auxiliary. Since the car cinostatic is prepared into a fatty emulsion safe to the human body, it has high local action, the purpose is attained by a small amount of administration, and side effects can be prevented.
INTRODUCTION: An area of rehabilitation research in burns is the impact of co-morbidities on disease trajectory. Obesity is a comorbidity of increasing public health concern, but its role remains controversial regarding burn injury and physical recovery. Our aim was to evaluate the association between body mass index (BMI) categories as a measure of obesity at discharge and self-reported physical function (PF) during recovery of adult burn survivors.
METHODS: This is a retrospective study on data collected by four major US burn centers, which contribute to the Burn Model System National Database. The data included BMI obtained at hospital discharge and self-reported PF-mobility, using the PROMIS measures assessed at 6, 12, and 24 months after burn. Subjects were classified into weight status categories based on BMI: underweight (BMI <18.5), normal weight (18.5 ≤ BMI <25), overweight (25 ≤ BMI <30), obesity class 1 (30 ≤ BMI <35), obesity class 2 (35 ≤ BMI <40), and obesity class 3 (BMI ≥40). Mixed-effects linear regression models were used to assess the association between BMI categories and PF scores over time, adjusted for patient and injury characteristics.
RESULTS: A total of 496 adult burn patients aged 47 ± 16 years were included, with mean total body surface area (TBSA) burned of 18 ± 19 % and mean BMI at discharge of 28 ± 7 kg/m2. PROMIS PF scores significantly improved over time in the recovery phase after burn (time effect, p < 0.001). Compared to overweight burn patients, normal-underweights exhibited lower PF score by an average of 4.06 units (p = 0.001) but scores increased linearly by an estimated 0.17 units per month (p = 0.01) over the 24 months after discharge. Similarly, compared to overweight burn patients, class 1 obese reported lower PF score by a mean 2.67 units (p = 0.07) but PF increased linearly by 0.15 units per month (p = 0.07) over the 24 months after discharge. These findings were independent of the effects of age at discharge, sex, TBSA burned, and hand and leg burn.
CONCLUSION: Being overweight was associated with improved and faster recovery of PF scores compared to normal, underweight, and obese burn patients during long-term recovery. Hence, our data suggests that long-term recovery and restoration of PF in adult burn survivors is not compromised by a small excess in body weight.
Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 2 months follow-up.